Reference,Reference: DOI,Assay,Section,Pre-vaccine Infection,Vaccine,# Shots,Months,Host,Control,Control: NT50 Cmp,Control: NT50 GeoMean,Control: NT50 GSD,Variant,Variant: Pos,Variant: Mutations,# Results,Potency: NT50 Cmp,Potency: NT50 GeoMean,Potency: NT50 GSD,Fold Reduction: Cmp,Fold Reduction: Median
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1380.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,500.0,1.0,=,2.8
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1963.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,614.0,1.0,=,3.2
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1010.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,273.0,1.0,=,3.7
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1305.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,419.0,1.0,=,3.1
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,1879.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,638.0,1.0,=,2.9
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,2028.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,568.0,1.0,=,3.6
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,1m,Human,Wild Type (B.1),=,856.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,203.0,1.0,=,4.2